Estimations des analystes de Wall Street pour Alkermes plc (ALKS): objectif de cours de consensus, recommandations achat/conserver/vente et prévisions de revenus, BPA et EBITDA pour les prochains exercices.
Surprises de Résultats Récentes
| Date | BPA Réel | BPA Estimé | vs Est. |
|---|---|---|---|
| 2026-10-28 | $-0.08 | ||
| 2026-07-28 | $0.70 | $-0.03 | +2650.1% |
| 2026-05-05 | $-0.40 | $-0.57 | +29.8% |
| 2026-02-25 | $0.34 | $0.43 | -20.9% |
| 2025-10-28 | $0.49 | $0.37 | +32.9% |
| 2025-07-29 | $0.52 | $0.41 | +26.8% |
| 2025-05-01 | $0.13 | $0.25 | -48.9% |
| 2025-02-12 | $1.04 | $0.81 | +28.4% |
Ratios de valorisation
| Ratio P/E | 112.07 |
| Prix / Valeur comptable | 4.16 |
| Rendement du dividende | 0.00% |
Compte de Résultat (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenus | $745.7M | $903.4M | $1.09B | $1.17B | $1.04B | $1.17B | $1.11B | $1.66B | $1.56B | $1.48B |
| Coût des Ventes | $132.1M | $154.7M | $176.4M | $180.4M | $178.3M | $197.3M | $218.1M | $253.0M | $245.3M | $196.5M |
| Marge Brute | $613.6M | $748.6M | $917.9M | $990.6M | $860.4M | $976.4M | $893.7M | $1.41B | $1.31B | $1.28B |
| R&D | $387.1M | $412.9M | $425.4M | $512.8M | $394.6M | $290.9M | $272.7M | $270.8M | $245.3M | $324.0M |
| Frais Généraux | $374.1M | $421.6M | $526.4M | $599.4M | $538.8M | $549.6M | $590.8M | $689.8M | $645.2M | $714.5M |
| Charges Opérationnelles | $822.2M | $896.5M | $1.02B | $1.17B | $972.9M | $878.7M | $899.8M | $996.2M | $891.7M | $1.03B |
| Résultat Opérationnel | -$208.7M | -$147.9M | -$99.1M | -$175.5M | -$112.4M | $97.7M | -$6.1M | $414.1M | $420.6M | $254.0M |
| EBITDA | -$105.2M | -$32.7M | -$7.9M | -$103.0M | -$6.0M | $177.6M | $59.8M | $519.5M | $494.9M | $330.9M |
| Charges d'Intérêt | $14.9M | $12.0M | $15.4M | $13.6M | $8.7M | $11.2M | $13.0M | $23.0M | $22.6M | $12.3M |
| Résultat Avant Impôts | -$214.4M | -$143.3M | -$127.0M | -$197.1M | -$96.5M | $87.7M | -$31.1M | $421.5M | $443.8M | $291.4M |
| Impôts | -$5.9M | $14.7M | $12.3M | -$436000 | $14.3M | $11.3M | $2.0M | -$97.6M | $71.6M | $49.8M |
| Résultat Net | -$208.4M | -$157.9M | -$139.3M | -$196.6M | -$110.9M | -$48.2M | -$158.3M | $355.8M | $367.1M | $241.7M |
| BPA | $-1.38 | $-1.03 | $-0.90 | $-1.25 | $-0.70 | $-0.30 | $-0.97 | $2.14 | $2.22 | $1.47 |
| BPA Dilué | $-1.38 | $-1.03 | $-0.90 | $-1.25 | $-0.70 | $-0.30 | $-0.97 | $2.10 | $2.17 | $1.43 |
| Actions en Circulation (Diluées) | $151.5M | $153.4M | $155.1M | $157.1M | $158.8M | $160.9M | $163.7M | $169.7M | $169.2M | $168.7M |
Prix
| Prix | $46.07 |
| Capitalisation | $7.7B |
| Bourse | NASDAQ |
| Pays | IE |
Entreprises liées: ACAD · ACLX · AKRO · ARWR · CRSP · KYMR · PCVX
Explorer le secteur: Healthcare · Drug Manufacturers - Specialty & Generic
Plus de sections de ALKS: Vue d'ensemble · Financiers · Valorisation · Statistiques · Technique · Actionnariat · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions